Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Provention Bio

    • Home
    • Provention Bio
Company Drug

Q1 2023 financial report: AstraZeneca leads innovation in China, Sanofi’s sales in China decline

Fineline Cube Apr 28, 2023

Several multinational companies (MNCs) have released their Q1 2023 financials, showing a varied performance over...

Recent updates

  • Qilu Pharma’s QLS31905 Wins FDA Orphan Drug Designation – First‑in‑Class Claudin18.2/CD3 Bispecific Enters Phase III for Pancreatic Cancer
  • WuXi Biologics Reports 2025 Revenue Growth 16.7% – Net Profit Surges 46.3% on Record 209 New Projects
  • Bayer/Regeneron’s Eylea HD Wins Japan Approval for RVO – Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections
  • Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise
  • Sanofi’s Dupixent Wins Japan Approval for Bullous Pemphigoid – Seventh Indication Expands IL‑4/IL‑13 Franchise
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Qilu Pharma’s QLS31905 Wins FDA Orphan Drug Designation – First‑in‑Class Claudin18.2/CD3 Bispecific Enters Phase III for Pancreatic Cancer

Company

WuXi Biologics Reports 2025 Revenue Growth 16.7% – Net Profit Surges 46.3% on Record 209 New Projects

Company Drug

Bayer/Regeneron’s Eylea HD Wins Japan Approval for RVO – Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections

Company Deals

Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.